University of Pittsburgh, Pittsburgh, Pennsylvania.
University College London Medical School, Royal Free Hospital, London, UK.
Arthritis Rheumatol. 2016 Apr;68(4):993-1003. doi: 10.1002/art.39490.
Although diffuse cutaneous systemic sclerosis (dcSSc) is associated with a reduction in life expectancy, there are no validated prognostic models for determining 5-year mortality in patients with dcSSc. The objective of this study was to derive and validate a rule for predicting 5-year mortality in patients with early dcSSc.
We studied an inception cohort of 388 US Caucasian patients with early dcSSc (<2 years from the appearance of the first symptom). Predefined baseline variables were analyzed in a stepwise logistic regression model in order to identify factors independently associated with 5-year all-cause mortality. We rounded the beta weights to the nearest integer and summed the points assigned to each variable in order to stratify patients into low-risk (<0 points), moderate-risk (1-2 points), and high-risk (≥3 points) groups. We then applied this rule to an external validation cohort of 144 Caucasian patients with early dcSSc from the Royal Free Hospital cohort and compared stratum-specific 5-year mortality.
Six independent predictors (rounded beta weight) comprised the model: age at first visit (points allotted: -1, 0, or 1), male sex (points allotted: 0 or 1), tendon friction rubs (points allotted: 0 or 1), gastrointestinal involvement (points allotted: 0 or 1), RNA polymerase III antibodies (points allotted: 0 or 1), and anemia (points allotted: 0 or 1). The 3-level risk stratification model performed well, with no significant differences between the US derivation cohort and the UK validation cohort.
We derived and externally validated, in US and UK cohorts, an easy-to-use 6-variable prediction rule that assigns low-risk, moderate-risk, and high-risk categories for 5-year mortality in patients with early dcSSc. Only history, physical examination, and basic laboratory assessments are required.
尽管弥漫性皮肤系统性硬皮病(dcSSc)与预期寿命缩短相关,但目前尚无用于确定 dcSSc 患者 5 年死亡率的经过验证的预后模型。本研究旨在建立并验证一种预测早期 dcSSc 患者 5 年死亡率的规则。
我们研究了一个由 388 名美国白种人早期 dcSSc 患者(从首发症状出现到研究入组时间<2 年)组成的队列。采用逐步逻辑回归模型对预设的基线变量进行分析,以确定与 5 年全因死亡率独立相关的因素。我们将β权重四舍五入至最接近的整数,并对每个变量分配的分数求和,以将患者分层为低危(<0 分)、中危(1-2 分)和高危(≥3 分)组。然后,我们将该规则应用于来自皇家自由医院队列的 144 名早期 dcSSc 白人患者的外部验证队列,并比较各分层的 5 年死亡率。
该模型包含 6 个独立的预测因素(四舍五入的β权重):首次就诊时的年龄(赋值点:-1、0 或 1)、男性(赋值点:0 或 1)、肌腱摩擦音(赋值点:0 或 1)、胃肠道受累(赋值点:0 或 1)、RNA 聚合酶 III 抗体(赋值点:0 或 1)和贫血(赋值点:0 或 1)。该 3 级风险分层模型具有良好的表现,在美国队列和英国验证队列之间无显著差异。
我们在美国和英国队列中建立并验证了一种简单易用的 6 变量预测规则,可对早期 dcSSc 患者的 5 年死亡率进行低危、中危和高危分类。该规则仅需患者的病史、体格检查和基本实验室检查结果。